CLIMB BIO, INC. Foreign Currency Transaction Gain (Loss), Realized
CLIMB BIO, INC. (CLYM) reported Foreign Currency Transaction Gain (Loss), Realized of $248.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Cash Flow › Operating Activities
us-gaap:ForeignCurrencyTransactionGainLossRealized · last filed 2023-05-11
- CLIMB BIO, INC. foreign currency transaction gain (loss), realized for the quarter ending 2023-03-31 was $248.00K.
- CLIMB BIO, INC. foreign currency transaction gain (loss), realized for the quarter ending 2022-03-31 was -$157.00K.
- CLIMB BIO, INC. foreign currency transaction gain (loss), realized for the quarter ending 2021-12-31 was $98.00K, a 59.84% decline year-over-year.
- CLIMB BIO, INC. foreign currency transaction gain (loss), realized for the quarter ending 2021-09-30 was -$252.00K, a 25300.00% decline year-over-year.
- CLIMB BIO, INC. foreign currency transaction gain (loss), realized for fiscal 2022 was -$1.48M.
- CLIMB BIO, INC. foreign currency transaction gain (loss), realized for fiscal 2021 was -$170.00K, a 166.15% decline from fiscal 2020.
- CLIMB BIO, INC. foreign currency transaction gain (loss), realized for fiscal 2020 was $257.00K.
| Period end | Foreign Currency Transaction Gain (Loss), Realized 3 month | Foreign Currency Transaction Gain (Loss), Realized 6 month | Foreign Currency Transaction Gain (Loss), Realized 9 month | Foreign Currency Transaction Gain (Loss), Realized 12 month |
|---|---|---|---|---|
| 2023-03-31 | $248.00K 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | -$1.48M 10-K · filed 2023-03-06 | |||
| 2022-03-31 | -$157.00K 10-Q · filed 2023-05-11 | -$59.00K derived: sum of 2 quarters · filed 2023-05-11 | -$311.00K derived: sum of 3 quarters · filed 2023-05-11 | -$323.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $98.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$154.00K derived: sum of 2 quarters · filed 2023-03-06 | -$166.00K derived: sum of 3 quarters · filed 2023-03-06 | -$170.00K 10-K · filed 2023-03-06 |
| 2021-09-30 | -$252.00K 10-Q · filed 2021-11-08 | -$264.00K derived: sum of 2 quarters · filed 2021-11-08 | -$268.00K 10-Q · filed 2021-11-08 | -$24.00K derived: sum of 4 quarters · filed 2022-05-16 |
| 2021-06-30 | -$12.00K 10-Q · filed 2021-09-13 | -$16.00K 10-Q · filed 2021-09-13 | $228.00K derived: sum of 3 quarters · filed 2022-05-16 | $229.00K derived: sum of 4 quarters · filed 2022-05-16 |
| 2021-03-31 | -$4.00K 10-Q · filed 2022-05-16 | $240.00K derived: sum of 2 quarters · filed 2022-05-16 | $241.00K derived: sum of 3 quarters · filed 2022-05-16 | $218.00K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $244.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $245.00K derived: sum of 2 quarters · filed 2022-03-07 | $222.00K derived: sum of 3 quarters · filed 2022-03-07 | $257.00K 10-K · filed 2022-03-07 |
| 2020-09-30 | $1.00K 10-Q · filed 2021-11-08 | -$22.00K derived: sum of 2 quarters · filed 2021-11-08 | $13.00K 10-Q · filed 2021-11-08 | |
| 2020-06-30 | -$23.00K 10-Q · filed 2021-09-13 | $12.00K 10-Q · filed 2021-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |